go-v.orgdoi

Methylation of PAX1 gene promoter in the prediction of concurrent chemo-radiotherapy efficacy in cervical cancer

Xuanxuan Li, Xue Zhou, Manting Zeng, Yangying Zhou, Yu Zhang, Yu‐Ligh Liou, Hong Zhu · Journal of Cancer · 2021

  • DOI 10.7150/jca.57460
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2021

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2021

Abstract

Objectives: Cervical cancer is the fourth leading cause of cancer death among women worldwide.In currently, aberrant methylation of PAX1 is found in variety of solid tumors, including cervical cancer.In addition, the role of PAX1 gene methylation in cervical cancer and precancerous lesions screening has been confirmed in previous study.Here, we evaluated the predictive value of PAX1 methylation in concurrent chemo-radiotherapy (CCRT) outcomes in cervical cancer.Methods: This study enrolled 82 cervical cancer patients from August 2018 to August 2020.We compared the clinical results between different PAX1 methylation status.Hyper-methylation patients were subjects to MRI and quantitative methylation-specific PCR (QMSP) for PAX1 before, in the middle, immediately after, 1 month and 3 months after CCRT.The changes in PAX1 methylation during CCRT were analyzed.Results: The lower PAX1 methylation status were related to a poor tumor response.Based on the MRI findings three months post-treatment, the hypermethylated patients were classified into the complete response (CR; n=50) and partial remission (PR; n=18) groups.The average PAX1 △Cp value of CR and PR groups before radiotherapy was 5.08±1.98 and 4.32±2.00respectively, and after concurrent chemo-radiotherapy was significantly increased to 17.35±4.96and 16.99±6.17,respectively (P<0.05).Furthermore, the PAX1 △Cp value between CR and PR groups were significantly different at mid-treatment and performed well in predicting short-term efficacy (AUC 0.84) in this period, and its sensitivity and specificity for predicting PR were 0.72 and 0.88, respectively.

Conclusion:The PAX1 methylation level may predict the sensitivity and efficacy of CCRT in cervical cancer.

Open the resolved locator · 10.7150/jca.57460

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:17 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v12p5136.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.